Trastuzumab deruxtecan - AstraZeneca/Daiichi Sankyo
Alternative Names: DS 8201; DS 8201a; ENHERTU; Enhertu; fam-trastuzumab deruxtecan; fam-trastuzumab deruxtecan-nxki; T-DXd; VRN-101099Latest Information Update: 23 Aug 2024
At a glance
- Originator Daiichi Sankyo Company
- Developer AstraZeneca; Bristol-Myers Squibb; Daiichi Sankyo Company; Medica Scientia Innovation Research; Seagen
- Class Antineoplastics; Camptothecins; Drug conjugates; Immunoconjugates; Monoclonal antibodies
- Mechanism of Action DNA topoisomerase I inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Breast cancer; Gastric cancer; HER2 positive breast cancer; Non-small cell lung cancer
- Registered Adenocarcinoma; Solid tumours
- Phase II Biliary cancer; Colorectal cancer; Uterine cancer
- Phase I/II Urogenital cancer
Most Recent Events
- 20 Aug 2024 Trastuzumab deruxtecan - AstraZeneca/Daiichi Sankyo receives Breakthrough Therapy status for Breast cancer (Inoperable/Unresectable, Metastatic disease) in USA
- 19 Aug 2024 The European Medicines Agency (EMA) validates the Type II variation application for trastuzumab deruxtecan monotherapy for the treatment of unresectable or metastatic HER2 low/HER2 ultralow breast cancer who have received at least one endocrine therapy
- 13 Aug 2024 Registered for Adenocarcinoma (Late-stage disease, Metastatic disease, Monotherapy, Second-line therapy or greater) in China (IV)